Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 13;5:16055. doi: 10.1038/boneres.2016.55

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Percentage changes in serum albumin-corrected calcium (a), serum phosphorus (b), serum tartrate-resistant acid phosphatase (TRACP)-5b (c), and urinary N-terminal telopeptide of type I collagen (NTX) (d) at pretreatment and at 1 week (w), 1, 2, 4, 8, 12, 15, 18, 21 and 24 months (m). Solid line: denosumab group; dotted line: combination (denosumab and teriparatide) group. Results are expressed as mean±s.e. ^#P<0.05, significant difference between the denosumab and combination groups at each time point. **P<0.01, significant difference at 1 week (w), 1, 2, 4, 8, 12, 15, 18, 21 and 24 months (m), compared with pretreatment in either the denosumab or combination group.